Engrail Therapeutics, a neuroscience firm based in San Diego, successfully closed its Series B funding round, raising an impressive $157 million. The funding was co-led by F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from Healthcare investor Eights Road Ventures, RiverVest Venture Partners, and Red Tree Venture Capital.
Engrail Therapeutics aims to utilise the investment to propel its pipeline through various stages of clinical development. The company is focused on developing innovative therapies to address the unmet medical needs of patients suffering from a range of neurological disorders, including anxiety disorders, depression, post-traumatic stress disorder, and rare neurodegenerative diseases.
[Sign up here to never miss these candid conversations delivered straight to your inbox.]
